GENinCode (LSE:GENI) is approaching a busy period of regulatory milestones, with the predictive genetics company planning to submit its flagship heart disease risk test to the US Food and Drug Administration in November 2026 and to file under European rules in December. Its interim results, published on 29 September 2026, showed lower revenue and a narrower loss, and confirmed that its cash runway extends into the first quarter of 2027, putting funding and commercial traction firmly in focus.

What the company does

GENinCode is a UK-based predictive genetics business focused on the prevention of cardiovascular disease, with an additional interest in ovarian cancer risk. It offers genetic risk tests based on blood or saliva samples through operations in the UK, Spain and the United States. Its main products include CARDIO inCode-Score, a polygenic risk score for coronary artery disease; LIPID inCode, a test for familial hypercholesterolaemia that is currently its main revenue driver; and the ROCA ovarian cancer risk algorithm, which has been adopted by University College London Hospitals.

Latest developments

According to the interim report, clinical validation of CARDIO inCode-Score by Kaiser Permanente has been completed, with statistical analysis under way ahead of an FDA De Novo submission expected in November 2026. An EU filing under the In Vitro Diagnostic Regulation is expected in December. The company also pointed to updated guidelines from the American College of Cardiology and American Heart Association in March 2026, which recognise coronary artery disease polygenic risk scores as a risk enhancer in heart disease prevention.

On 28 August 2026, GENinCode reported preliminary results from a real-world pilot of 584 moderate-risk patients in Catalonia, presented at the ESC Congress in Munich. Genetic results changed the overall risk assessment for 42.6% of patients, and average cardiovascular risk and LDL cholesterol both fell during follow-up. The company cautioned that the study was non-randomised and that further analyses are continuing, with full publication expected in the first half of 2027.

Commercial progress has been mixed. More than 80 US sites have been onboarded, mainly for LIPID inCode, but sales through its partnership with Thermo Fisher Scientific have been slower than expected. Chief executive Matthew Walls said the company had hoped to achieve greater traction from the Thermo Fisher launch.

Financial picture

Revenue for the six months to 30 June 2026 fell to £1.13 million from £1.60 million, which management attributed to weaker NHS activity and non-recurring Spanish pilot revenue. Spain remained the largest region. The adjusted EBITDA loss narrowed to £2.26 million from £2.54 million, and the loss after tax was £2.52 million. Cash was £1.98 million at the end of June, up from £0.83 million at the end of 2025, after a placing at 1p per share in February raised £4.66 million gross. The company expects full-year revenue of about £3.2 million and does not pay a dividend.

Sector and index context

GENinCode is one of a number of small healthcare technology companies on the FTSE AIM All Share Index seeking to bring genetic and precision diagnostics into routine clinical use. Growing guideline recognition for polygenic risk scores is a potential tailwind, but reimbursement and adoption by health systems tend to move slowly.

Key risks

With a cash runway into early 2027, the company is likely to need further funding, which could dilute shareholders. Regulatory outcomes are uncertain, partner-led sales have underperformed, and revenue depends on public health system budgets in the UK and Spain.

What to watch next

The FDA submission in November and the EU filing in December are the key near-term catalysts. Investors will also watch the Thermo Fisher rollout, first samples from partners in Mexico, adoption decisions in Spain and any funding news.